Research Analysts Issue Forecasts for LEXX Q2 Earnings

Lexaria Bioscience Corp. (NASDAQ:LEXX) – Investment analysts at Zacks Small Cap issued their Q2 2025 earnings per share estimates for shares of Lexaria Bioscience in a report issued on Tuesday, January 28th. Zacks Small Cap analyst J. Vandermosten forecasts that the company will post earnings per share of ($0.14) for the quarter. The consensus estimate for Lexaria Bioscience’s current full-year earnings is ($0.42) per share. Zacks Small Cap also issued estimates for Lexaria Bioscience’s Q3 2025 earnings at ($0.14) EPS, FY2025 earnings at ($0.57) EPS and FY2026 earnings at ($0.45) EPS.

Separately, HC Wainwright cut their price target on shares of Lexaria Bioscience from $10.00 to $7.00 and set a “buy” rating for the company in a report on Friday, January 24th.

Lexaria Bioscience Price Performance

Shares of NASDAQ LEXX opened at $1.82 on Thursday. The stock has a market capitalization of $31.94 million, a PE ratio of -3.64 and a beta of 0.98. Lexaria Bioscience has a one year low of $1.43 and a one year high of $6.85. The business’s fifty day moving average price is $2.14 and its 200-day moving average price is $2.70.

Lexaria Bioscience (NASDAQ:LEXX) last posted its quarterly earnings results on Friday, January 10th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.04). Lexaria Bioscience had a negative net margin of 1,473.04% and a negative return on equity of 88.88%.

Hedge Funds Weigh In On Lexaria Bioscience

Several institutional investors have recently modified their holdings of LEXX. Geode Capital Management LLC lifted its stake in shares of Lexaria Bioscience by 31.0% in the 3rd quarter. Geode Capital Management LLC now owns 150,391 shares of the company’s stock valued at $459,000 after acquiring an additional 35,608 shares during the last quarter. Renaissance Technologies LLC bought a new stake in Lexaria Bioscience in the second quarter valued at approximately $63,000. XTX Topco Ltd boosted its stake in shares of Lexaria Bioscience by 47.8% during the third quarter. XTX Topco Ltd now owns 18,626 shares of the company’s stock valued at $57,000 after purchasing an additional 6,024 shares during the period. HighTower Advisors LLC bought a new position in shares of Lexaria Bioscience in the third quarter worth approximately $40,000. Finally, Byrne Asset Management LLC increased its stake in shares of Lexaria Bioscience by 132.1% in the fourth quarter. Byrne Asset Management LLC now owns 13,000 shares of the company’s stock worth $27,000 after buying an additional 7,400 shares during the period. 13.06% of the stock is currently owned by institutional investors.

Insider Activity

In other news, CEO Richard Christopher purchased 22,828 shares of the stock in a transaction on Monday, December 2nd. The shares were acquired at an average price of $2.24 per share, for a total transaction of $51,134.72. Following the completion of the transaction, the chief executive officer now directly owns 22,828 shares of the company’s stock, valued at approximately $51,134.72. This trade represents a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 26.40% of the company’s stock.

Lexaria Bioscience Company Profile

Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods.